Showing 5201-5210 of 5801 results for "".
- Novartis Drug Odomzo Gains EU Approval for Locally Advanced Basal Cell Carcinomahttps://practicaldermatology.com/news/novartis-drug-odomzo-gains-eu-approval-for-locally-advanced-basal-cell-carcinoma/2458887/Novartis has announced the European Commission approval of Odomzo® (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to cura
- Provectus Receives Patent for Investigational Melanoma Agent PV-10https://practicaldermatology.com/news/provectus-receives-patient-for-investigational-melanoma-agent-pv-10/2458891/Provectus Biopharmaceuticals, Inc. has received a patent from the US Patent and Trademark Office, protecting the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver. Specifically, the patent covers the use of PV-10 in combination wit
- MEG 21 with Supplamine Now Available in Treatment Rooms with New Professional Size Dispensershttps://practicaldermatology.com/news/meg-21-with-supplamine-now-available-in-treatment-rooms-with-new-professional-size-dispensers/2458892/MEG 21 with Supplamine is a science-based company specializing in skin products for the face, neck, décolleté, and arms that uniquely remove toxic sugar from skin. Dynamis Skin Science, the parent company, was founded in 1997, based on the work of scientists initially working at Fox
- LaserCap Receives 510(k) Clearance for Hair Treatment Devicehttps://practicaldermatology.com/news/lasercap-receives-510k-clearance-for-hair-treatment-device/2458894/LaserCap® Company has received FDA 510(k) clearance for the
- Cellfina Cleared to Treat Cellulite for Up to Two Yearshttps://practicaldermatology.com/news/cellfina-cleared-to-treat-cellulite-for-up-to-two-years/2458898/The Cellfina System from Ulthera, Inc. has received FDA clearance for the long-term improvement in the appearance of cellulite on the buttocks and thighs with no loss of benefit for up to 2 years. Ulthera is a a wholly-owned subsidiary of Merz, Inc. The
- Organogenesis Launches PuraPly Wound Management Productshttps://practicaldermatology.com/news/organogenesis-launches-puraply-wound-management-products/2458905/Organogenesis Inc. launched its new PuraPly™ wound management products, including PuraPly Antimicrobial (PuraPly AM), the first FDA-cleared purified collagen matrix with polyhexamethylene biguanide hydrochloride (PHMB) antimicrobial agent. PuraPly and PuraPly AM are the la
- Research: Slow-release Nitric Oxide Particles May Reduce Inflammatory Acnehttps://practicaldermatology.com/news/research-slow-release-nitric-oxide-particles-may-reduce-inflammatory-acne/2458910/GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology. This research, published in the Journal of Investigative Dermatology, identified that the nanoparticles were eff
- CMS and AMA Announce Efforts to Ease ICD-10 Transitionhttps://practicaldermatology.com/news/cms-and-ama-announce-efforts-to-ease-icd-10-transition/2458913/The Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) are initiating efforts to continue to help physicians get ready ahead of the October 1 deadline to move from ICD-9 to ICD-10 coding for medical diagnoses and inpatient hospital procedures. In respons
- Unilever to Acquire Muradhttps://practicaldermatology.com/news/unilever-to-acquire-murad/2458916/Unilever has signed an agreement to acquire Murad. This follows the recent acquisitions of Dermalogica, Kate Somerville, and REN, which jointly position Unilever as a key player in the personal care prestige segment. Murad was founded in 1989 in Los Angeles. Howard Murad MD, a dermatologi
- Restylane Lyft Approved for Cheek Augmentation and Midface Contour Deficiencieshttps://practicaldermatology.com/news/restylane-lyft-approved-for-cheek-augmentation-and-midface-contour-deficiencies/2458917/The FDA approved Galderma's Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. Restylane Lyft, formerly marketed as Perlane-L, is an injectable gel used to increase volume and smooth wrinkles in the face. With t